Study Phase 3

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy

Trial Information

Generic NameEpoetin alfaProduct NamePROCRIT®Therapeutic AreaBlood and Lymph ConditionsEnrollment939% Female100%% White98%
Product ClassColony-Stimulating FactorsSponsor Protocol NumberCR004414 (EPO-INT-76) DOUBLE BLINDData PartnerJohnson & JohnsonCondition StudiedAnemia, Neoplasms, BreastMean/Median Age (Years)55.4

Supporting Documentation

  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Analysis Datasets Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.